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Objective: To report clinical and dosimetric outcomes of
a consecutive series of patients with anal cancer treated
with volumetric-modulated arc therapy (VMAT) concom-
itant to chemotherapy (CT).
Methods: A cohort of 39 patients underwent VMAT
employing a schedule consisting of 50.4Gy/28 fractions
to the gross tumour volume (GTV) and 42Gy/28 fractions
to the elective nodal volumes for patients with cT2N0
disease. Patients with cT3–T4/N0–N3 tumours were pre-
scribed 54Gy/30 fractions to the GTV and 50.4Gy/30
fractions to the gross nodal volumes if sized #3cm or
54Gy/30 fractions if . 3cm. Elective nodal regions were
given 45Gy/30 fractions. CT was administered concurrently
following Nigro’s regimen. The primary end point was acute
toxicity. Secondary end points were colostomy-free survival
(CFS), disease-free survival (DFS), cancer-specific survival
(CSS) and overall survival (OS). Dosimetric data are also
provided.
Results: Median follow-up was 21 months. Maximum acute
toxicities were: dermatologic—G3: 18%; gastrointestinal–G3:
5%; genitourinary–G3: 2%; anaemia—G2: 7%; leukopenia—
G3: 28%; G4: 8%; neutropenia—G3: 13%; G4: 18%; thrombo-
cytopenia—G3: 11%; and G4: 2%. The actuarial 2-year CFS
was 77.9% [95% confidence interval (CI): 54–90.4%].
Actuarial 2-year OS and CSS were 85.2% (95% CI:
60.1–95.1%), while DFS was 75.1% (95% CI: 52.4.7–88.1%).
Conclusion: Our clinical results support the use of VMAT
as a safe and effective intensity-modulated radiother-
apy (IMRT) option in the combined modality treat-
ment of anal cancer, with consistent dosimetry, mild
toxicity and promising sphincter preservation and
survival rates.
Advances in knowledge: IMRT is a standard of care for
patients with anal cancer, and VMAT is a robust technical
solution in this setting.
INTRODUCTION
Combined modality therapy with concomitant chemo-
radiation is presently considered as the standard treatment
option for patients with squamous cell anal cancer, pro-
viding consistent rates of locoregional control (LC), overall
survival (OS) and sphincter preservation.1 Long-term
results of the Radiation Therapy Oncology Group
(RTOG) 98-11 trial combining external-beam radiotherapy
(EBRT) and concurrent 5-fluorouracil (5-FU)/mitomycin-C
(MMC) showed 5-year disease-free survival (DFS) and OS
rates of 67.8% and 78.3%, respectively, confirming valid
clinical results in this setting.2 Nevertheless, this treatment
regimen is frequently associated with a relevant acute toxicity
profile, regarding particularly cutaneous, genitourinary (GU)
and gastrointestinal (GI) districts, which may potentially be
detrimental to oncological outcomes.3 The same RTOG 98-11
trial reported crude rates of acute G3/G4 toxicities of 48% for
the skin and 35% for GI, mainly owing to the utilization of
non-conformal techniques, namely anteroposterior/
posteroanterior parallel opposed fields or four-field confor-
mal approaches, that deliver radiotherapy to a large amount
of normal tissues, exposing organs at risk (OARs) to un-
intended radiation.3 Intensity-modulated radiotherapy
(IMRT) may provide robust conformality and modulation,
abrupt dose fall-off and reliable consistency and, hence, it has
been implemented in several oncological scenarios.4–6 In the
context of anal cancer, IMRTmay potentially reduce the dose
to critical structures such as the bowel, bladder, genitalia,
perineal skin and bone marrow, increasing treatment overall
tolerability.7 Volumetric-modulated arc therapy (VMAT)
combines a rotational approach towards the patient and beam
modulation obtained with continuous modulation of multileaf
collimator, dose rate variations and gantry rotational speed dy-
namics. Few planning comparison studies demonstrated that
rotational approaches are technically feasible in the context of
anal cancer and may spare OARs.8,9 We herein present the
results of a consecutive series of patients with anal cancer ho-
mogeneously treated with concurrent chemoradiotherapy
employing VMAT, reporting on both clinical and dosimetric
outcomes.
METHODS AND MATERIALS
Eligibility criteria
All patients included in the present analysis had a histologically
proven diagnosis of squamous cell anal carcinoma involving
either the anal canal or margin and were treated within the
Radiation Oncology Department of the University of Turin,
Italy. Disease stage was defined following the 2002 American
Joint Committee on Cancer classification with patients with
clinical stage T1–T4, N0–N3 included. Other inclusion criteria
comprehended an Eastern Cooperative Oncology Group perfor-
mance status of 0–1, age 18–80 years, suitable haematological
parameters (neutrophils $1.53 109 l21 and platelets
$1003 109 l21) and adequate renal and liver functions. Exclu-
sion criteria included systemic spread at presentation, prior
pelvic radiotherapy, medical contraindications to combina-
tion therapy, bowel occlusion symptoms and/or GI bleeding,
malabsorption syndrome, peripheral neuropathy, psychiatric
disease hampering compliance to therapy, pregnancy and breast-
feeding. Written informed consent was obtained for all patients.
Pre-treatment evaluation
Patients were evaluated by the GI Tumour Board of our hospital
including all related specialities (radiation and medical oncology
and abdominal surgery). The medical examination was made of
whole clinical history and objective assessment with digital rectal
exam and complete blood check. Staging was performed with total-
body computed tomography scan, pelvic MR, 18 fludeoxyglucose-
positron emission tomography (PET) and/or inguinal sentinel
lymph node biopsy.1
Radiotherapy
Patients had a virtual simulation procedure in supine position
with both an indexed shaped knee rest and ankle support
(CIVCO Medical Solutions, Kalona, IA), without custom im-
mobilization. A computed tomography scan was performed with
3-mm slice thickness axial images acquired from the top of the
L1 vertebral body to the mid-femoral bones. An isocentre was
determined on computed tomography simulation software
Oncentra MasterPlan® v. 3.0 (Nucletron B.V., Veendhal, Neth-
erlands) in the pelvic region and marked on the patient’s skin
under laser guidance for daily setup. The gross tumour volume
(GTV) comprised all primary and nodal macroscopic disease.
GTV was defined based on the MRI and PET information after
a non-rigid co-registration with planning computed tomography
using the Velocity software (Varian Medical System Inc., Palo
Alto, CA). Primary and nodal GTVs were expanded isotropically
by 2 and 1 cm, respectively, to obtain subsequent clinical target
volumes (CTVs) and then optimized to avoid bones and soft
tissues. The prophylactic CTV included the mesorectal region
and nodal areas, namely the inguinal, external and internal iliac,
obturator and perirectal. For patients with cT4 and/or N2/N3
disease, presacral nodal areas were also encompassed in the CTV.
Nodal areas were delineated employing a 1-cm isotropic margin
around regional vessels and then modified to exclude bones and
muscles. Thereafter, a 10-mm isotropic margin was added for the
corresponding planning target volume (PTV) to account for organ
motion and setup errors.10,11 Dose prescription for target volumes
was taken from Kachnic et al12 and related to the clinical stage
at presentation. Patients with cT2N0 disease were prescribed
50.4Gy/28 fractions to the gross tumour PTV and 42Gy/28 frac-
tions to the elective nodal PTV. Patients staged as cT3–T4/N0–N3
were given 54Gy/30 fractions to the macroscopic anal PTV, while
clinical nodes were prescribed 50.4Gy/30 fractions if #3 cm or
54Gy/30 fractions if .3 cm; elective nodal PTV was prescribed
45Gy/30 fractions. During the treatment-planning phase, objectives
for target volumes were set so that for PTV, V95 should be at least
95%, V110 #10% and #2% should receive ,95% of prescribed
dose. Dose constraints for OARs were inspired by Kachnic et al12
and included V45, 20ml, V35, 150ml and V30,200ml for the
small and large bowel, V50, 5%, V40, 35% and V35, 50% for
the bladder, V40,5%, V30,35% and V20, 50% for the external
genitalia, V44,5% and V40,35% for the femoral heads and
V50,5% and V20,50% for the iliac bone. To compute VMAT,
Elekta Monaco® was used as the treatment-planning system (v. 3.2)
(Elekta AB, Stockholm, Sweden), optimizing treatment with bi-
ological cost functions (Poisson statistics cell kill, serial and parallel
complication models). The geometrical approach to treatment vol-
umes employed a 360° single-arc or dual-arc approach after system
upgrade. A simultaneous integrated boost (SIB) approach was
employed for all patients. Radiotherapy delivery was performed
under cone-beam computed tomography image guidance, with daily
treatment couch repositioning performed after automatic matching of
cone-beam computed tomography images and reference planning
computed tomography. Images were matched by employing a soft-
tissue window and prioritized to the primary tumour and nodal target
volumes with a favourable visualization process.
Chemotherapy
All patients received concurrent chemotherapy (CT), consisting of
5-FU (1000mgm22 day) given as continuous infusion along 96h
(Days 1–5 and 29–33) associated with MMC (10mgm22) given as
bolus (Days 1 and 29). A total of two concurrent cycles were planned
at the baseline for each patient. Blood cell counts were performed on
a routine basis prior to each CT cycle. Prophylactic antiemetic
medications were given as intravenous granisetron 3mg and dexa-
methasone 8mg. CT discontinuation or drug modification were
planned in case of G3–G4 toxicities.
Clinical assessment
Acute toxicity was scored according to the Common Toxicity
Criteria for Adverse Events (NCI-CTCAE) scale v. 3.0, evaluating
GU, GI, haematologic, dermatologic, genital and osseous events.
The worst episode of toxicity for each category was considered as
an acute event, if occurring within 90 days from the end of
treatment. After 90 days, all toxicities were classified as late. Follow-
up included digital rectal examination and anoscopy at 4, 8, 12 and
26 weeks. MRI was performed at 12 weeks and an anal canal
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bioptic sampling was carried out at 26. If no residual disease was
found at pathology examination, a complete response was assigned.
A salvage abdominoperineal resection was generally recommended
for persistent disease (at pathology) or for locally progressive or
recurrent disease (at imaging and pathology). Conservative salvage
treatment strategies were also considered when deemed appropriate.
Statistical analysis
Definition of disease recurrence included local recurrence if
relapse in the anal canal and/or anal margin and/or mesorectum
was detected. Regional relapse comprised disease at draining
lymph nodes (inguinal and pelvic nodes), while systemic
recurrence included evidence of disease arising elsewhere.
For LC, we took into account local and regional failures. For
cancer-specific survival (CSS), we considered death due to dis-
ease. OS considered death of any cause. DFS included all failures
and cancer-related deaths. Colostomy-free survival took into
account death of any cause or definitive colostomy. Distant
metastasis-free survival included failures other than those oc-
curring in the anal region and regional nodes. Kaplan–Meier
Table 1. Patient characteristics
Variable N (%)
Age
Mean 66
Range 48–80
Sex
Female 27 (70)
Male 12 (30)
HIV status
Positive 3 (8)
Negative 36 (92)
Primary tumour site
Anal canal 31 (80)
Anal margin 8 (20)
T stage
T1 2 (5)
T2 28 (72)
T3 9 (23)
T4 0
N stage
N0 28 (72)
N1 2 (5)
N2 8 (20)
N3 1 (3)
Global stage
I 2 (5)
II 26 (67)
IIIA 2 (5)
IIIB 9 (23)
Grading
G1 1 (3)
G2 27 (71)
G3 11 (27)
Prophylactic colostomy
Yes 0 (0)
No 39 (100)
HIV, human immunodeficiency virus.
Table 2. Treatment characteristics
Variable N (%)
IMRT approach
Single arc 17 (46)
Dual arc 21 (54)
PTV dose tumour (Gy)
54Gy/30 fractions 26 (66.7)
50.4Gy/28 fractions 13 (33.3)
PTV dose-positive nodes (Gy)
54Gy/30 fractions 2 (5)
50.4Gy/30 fractions 9 (23)
PTV dose-negative nodes (Gy)
45Gy/30 fractions 28 (74)
42Gy/28 fractions 11 (26)
Chemotherapy
5-FU 1 MMC 39 (100)
Cycles
1 4 (10)
2 35 (90)
Chemotherapy dose reduction
Yes 2 (5)
No 37 (95)
Biopsy–RT interval (days)
Mean 83
Range 30–148
RT duration (days)
Mean 43
Range 38–54
RT breaks $ 3 days
Yes 4 (10)
No 35 (90)
5-FU, 5-fluorouracil; IMRT, intensity-modulated radiotherapy;
MMC, mitomycin C; PTV, planning target volume; RT, radiotherapy.
Full paper: Intensity-modulated radiotherapy for anal cancer treatment BJR
3 of 8 birpublications.org/bjr Br J Radiol;89:20150832
method was used to calculate survival curves and actuarial rates
of relapse. Wilcoxon signed-rank test was used to perform
univariate analysis. Multivariate analysis was performed using
stepwise Cox proportional hazard regression models. An even-
tual correlation between clinical prognostic factors and OS, CSS
and DFS and between dosimetric parameters and acute toxicity
was tested. The threshold for statistical significance was set at
p-value ,0.05. As continuous variables we considered: overall
treatment time (OTT) (days), time between biopsy and radio-
therapy start (days), treatment breaks (days) and age. As cate-
gorical variables we included: stage, staging procedure (PET vs
inguinal sentinel lymph node biopsy), tumour location (anal
canal vs anal margin), inguinal lymph node involvement, tu-
mour grading, sex, G3-G4 acute toxicity events and eventual CT
dose reduction. STATA® Statistical Software, v. 13.1 (Stata Corp,
College Station, TX) was employed for analysis.
RESULTS
A total of 39 patients were enrolled from April 2011 to January
2015. Detailed patient characteristics can be found in Table 1.
Patients had a mean age of 66 years (range 48–80 years) and
were mainly female (71%), human immunodeficiency virus
negative (92%), with an anal canal primary (80%), T2 stage
(72%), N0 (72%), G2 (71%) and without a preventive co-
lostomy (100%). Patients were mainly treated with a dual-arc
VMAT approach (54%). Most of the patients received 54Gy/30
fraction on the primary tumour PTV (66.7%) and 45Gy/30
fraction on the prophylactic nodal PTV (74%). Those with
macroscopic nodal involvement mostly received 50.4Gy/30 frac-
tions on the corresponding PTV (23%). The mean time occurring
between biopsy and start of radiotherapy was 83 days. Mean OTT
was 43 days. 12 (30%) patients had a treatment break, lasting on
average 2.2 days (including machine breakdown). Patients with
breaks $3 days were 10%. For details see Table 2.
Toxicity profile
Table 3 shows acute toxicity for the whole cohort. Maximum
detected events included: the skin (G3): 18%; GI (G3): 5%; GU
(G3): 2%; anaemia (G2): 7%; leukopenia (G3): 28%, (G4):8%;
neutropenia (G3): 13%; (G4): 18%; thrombocytopenia (G3):
11%; and (G4): 2%. Moist desquamation (skin), diarrhoea with
.7 stools per day (GI) and cystitis interfering with activities of
daily living (GU) were considered as G3 events. A total of 4 (10%)
out of 39 patients underwent a single cycle of concurrent 5-FU and
MMC because of major haematological toxicity, while 2 (5%)
patients had a 20% dose reduction during the second CT cycle. No
dosimetric factors [mean doses and dose–volume points (Vx) on
the dose–volume histogram] were found to be predictors of acute
toxicity. Only external genitalia V20 was found borderline signifi-
cant for acute G3–G4 events regarding the genitalia on univariate
analysis [odds ratio (OR): 1.04; p50.055; 95% confidence interval
(CI): 0.997–1.006].
Dosimetric outcomes
Dosimetric parameters regarding both treatment volumes and
OARs are presented in Table 4. For the bladder and large bowel,
planned dose constraints could not be met in 2 patients (5%). For
the external genitalia, constraints could not be met in 23/39 (59%)
patients for V20, in 15/39 (38%) patients for V30 and in 29/39
(74%) patients for V40. All others were met in the whole cohort.
Clinical outcomes
The median observation time was 21.5 months (range 6–
50 months). A total of five patients presented with local relapse
after combination therapy: four patients had local relapse only,
while one patient experienced both local and metastatic (liver and
lung) failure. Among locally relapsing patients, three patients were
salvaged with abdominoperineal resection, while one patient re-
ceived local excision and consolidation interstitial brachytherapy
after initial failure within the anal margin. One remaining patient
experienced nodal relapse within pelvic, lumbar-aortic and me-
diastinal lymph nodes. All metastatic patients received CT as part
of their salvage treatment. Overall, four patients died and all
deaths were cancer-related events. Actuarial 1-year and 2-year OS
were 100% and 85.2% (95% CI: 60.1–95.1%) (Figure 1). Given
that all deaths have a cancer-related cause, CSS corresponds to
OS. Actuarial 1-year and 2-year DFS were 100% and 84.5% (95%
CI: 63.7–93.9%) and 75.1% (95% CI: 52.4.7–88.1%) (Figure 2).
The actuarial probability of being alive at 1 and 2 years without
a colostomy (colostomy-free survival) was 88.4 % (95% CI:
68–96.1%) and 77.9% (95% CI: 54–90.4%) (Figure 3). On
Table 3. Acute toxicity
Acute toxicity
N (%)
G0 G1 G2 G3 G4
Skin 1 (2) 5 (13) 26 (67) 7 (18) 0
Gastrointestinal 1 (2) 12 (31) 24 (62) 2 (5) 0
Genitourinary 7 (18) 25 (64) 6 (16) 1 (2) 0
Genitalia 5 (13) 24 (62) 10 (25) 0 0
Anaemia 24 (62) 12 (31) 3 (7) 0 0
Leukopenia 5 (13) 9 (23) 11 (28) 11 (28) 3 (8)
Neutropenia 12 (31) 8 (20) 7 (18) 7 (18) 5 (13)
Thrombocytopenia 23 (59) 8 (20) 3 (8) 4 (11) 1 (2)
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Table 4. Dosimetric results
Volumes Parameters Mean SD
PTV
PTV—tumour
D98 (Gy)—50.4Gy 47.8 0.8
D2 (Gy)—50.4Gy 53.2 1.2
D98 (Gy)—54Gy 50.6 1.2
D2 (Gy)—54Gy 57.3 1.1
V95 (%) 96.2 3.1
V105 (%) 8.5 8.6
V107 (%) 2.2 4.1
PTV—elective volumes
D98 (Gy)—42Gy 39.4 0.6
D2 (Gy)—42Gy 52.3 1.5
D98 (Gy)—45Gy 41.5 1.5
D2 (Gy)—45Gy 55.1 1.3
V95 (%) 95.6 2.1
V105 (%) 36.2 12.5
V107 (%) 26.3 11.8
OARs
Bladder
V35 (%) 35.1 17.6
V40 (%) 17.7 13.1
V45 (%) 5.9 8.4
V50 (%) 1.3 2.9
D2 (Gy) 45.5 4.7
Mean dose (Gy) 30.2 4.9
Small intestine
V30 (cm
3) 149 110.6
V35 (cm
3) 108 89.4
V45 (cm
3) 15 9.4
D2 (Gy) 44.4 3.6
Mean dose (Gy) 25.4 8.2
Large intestine
V30 (cm
3) 123 116.2
V35 (cm
3) 78 65.2
V45 (cm
3) 13 12.4
D2 (Gy) 42.9 6.9
Mean dose (Gy) 18.9 4.7
External genitalia
V30 (%) 59.5 19.1
V35 (%) 35.9 16.4
V45 (%) 21.7 13.4
D2 (Gy) 52.3 5.6
Mean dose (Gy) 26.2 6.7
Femural heads
V30 (%) 36.3 17.1
V40 (%) 7.1 9.3
V45 (%) 0.6 1.8
(Continued)
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univariate and multivariate analysis, no independent variables
were found to be related to clinical outcomes.
DISCUSSION
Radiotherapy for the treatment of patients with anal cancer
has been historically delivered by employing two-dimensional or
three-dimensional (3D) solutions.2 This leads to the conse-
quence that a consistent part of normal tissues may be exposed
to unintended irradiation, with several OARs such as the
bladder, bowel, perineal region and bone marrow included within
treatment fields receiving medium-to-high-dose radiation.12
Combined concurrent chemoradiotherapy in anal cancer with no
IMRT use has been observed to have a high rate of GI (G3–G4:
35%, mainly diarrhoea) and haematologic (G3–G4: 61%) side
effects, as demonstrated in the RTOG 98-11 trial.3 IMRT provides
dosimetric advantages in terms of both target coverage and OARs
avoidance compared to 3D conformal EBRT in several oncolog-
ical scenarios.13–15 This is also evident in the context of anal
cancer, where several reports are available in the literature. In
a multi-institutional retrospective study, Salama et al reported
about IMRT as part of combined modality therapy, observing
a 15.1% G3 acute rate for GI, 37% for skin toxicity and 58.5% for
G3–G4 haematologic side effects.16 All G4 events were haema-
tologic (leukopenia: 30.2%; neutropenia: 34%). Up to 41.5% of
patients had treatment breaks, lasting an average 4 days.7 In
another interesting article, within a retrospective multi-
institutional study, Kachnic et al12 employed dose-painted
IMRT and reported a 7% G3 acute toxicity rate for GI, 5% rate
for GU, 5% for skin and 49% for haematologic events. In the
aforementioned series, G4 events included haematologic (12%),
GU (2%) and dermatologic (5%) toxicities. No G4 events were
seen for the GI tract. Radiotherapy breaks were observed in 40%
of patients. Median time was 2 days. Patients experiencing breaks
lasting more than 3 days were up to 35%. IMRT has been
demonstrated to be able to decrease the acute toxicity profile in
patients with anal cancer as compared with 3D conformal treat-
ments, as shown by Bazan et al and Choung et al, with a conse-
quent further advantage in terms of reduction in treatment
breaks.16,17. This side effect decrease has been shown not to affect
oncological outcomes as Dasgupta et al18 observed, within a pro-
pensity score analysis, that LC is not compromised by the use of
IMRT compared with standard techniques. All the aforemen-
tioned studies investigated the role of IMRT in anal cancer within
a retrospective framework. The only study that prospectively
tested the hypothesis that IMRT may potentially enlarge the
therapeutic window was the RTOG 05-29 phase II trial that in-
vestigated whether dose-painted IMRT may reduce by at least
15% the $ G2 GI and GU toxicity rates, compared with con-
ventional EBRT concurrent to 5-FU/MMC as delivered in the
RTOG 98-11 trial.19 Even if the primary end point of the trial was
Table 4. (Continued)
Volumes Parameters Mean SD
D2 (Gy) 41.4 3.6
Mean dose (Gy) 26.5 4.7
PBM
V5 (%) 93.6 5.9
V10 (%) 89.2 7.4
V20 (%) 74.2 8.7
V30 (%) 50.2 8.9
V40 (%) 23.9 7.5
Mean dose (Gy) 28.8 2.9
OARs, organs at risk; PBM, pelvic bone marrow; PTV, planning target volume; SD, standard deviation.
Figure 1. Actuarial overall survival. Figure 2. Actuarial disease-free survival.
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not reached, the study showed a significant reduction in acute G2
haematologic (73% vs 85% for RTOG 98-11), G3 GI (21% vs
36% for RTOG 98-11) and G3 dermatologic acute adverse events
(23% vs 49% for RTOG 98-11) compared with standard EBRT.19
Our results compared similarly with those of the aforementioned
reported series. For instance, G3 acute events were 18% for
dermatologic toxicity, 5% for GI, 2% for GU, 28% for leukopenia,
18% for neutropenia and 11% for thrombocytopenia. Grade 4
events were seen only for haematological toxicity (23% overall).
The acute toxicity profile of our series homogeneously treated
with a VMAT approach compares favourably with similar reports
employing other types of IMRT performed with different volu-
metric approaches. Tozzi et al reported on a consecutive series of
36 patients with anal cancer treated with the RapidArc solution,
observing a 13.9% rate of G3 dermatologic toxicity, 17.9% for G3
GI events and no GU G3 toxicity (33.3% of G2). Patients were
compared with a historical series of matched patients treated with
3D conformal EBRT, finding a significant decrease in toxicity.20
Yeung et al21 compared static vs volumetric IMRT delivered with
helical tomotherapy, observing an advantage in terms of target
coverage and lower dose to the bone marrow and external genitalia
for tomotherapy and better dosimetric outcomes with respect to
the bladder, femoral heads and peritoneal space for static IMRT.
The rate of $ G2 non-haematologic toxicities were 88.2%, 53%
and 5.9% for the skin, GI and GU, respectively, with the use of
helical tomotherapy, compared with 85%, 67% and 18% in our
series. Leukopenia, neutropenia, thrombocytopenia and anaemia$
G2 were 82.4%, 70.6%, 41.2% and 35.3%, respectively, for
tomotherapy and 64%, 49%, 21% and 7% in our series. In our
cohort, all patients were irradiated by employing an unconstrained
IMRT approach towards the pelvic bone marrow, since osseous
structures were not included within the optimization process for
selective avoidance. It has been demonstrated, for both cervical and
anal cancer treated with concomitant CT, that specific doses given
to certain volumes of pelvic bones have a significant correlation
with acute haematologic toxicity.22,23 On multiple regression
analysis, a higher volume of pelvic and lumbosacral bone marrow
receiving 5, 10, 15 and 20Gy was significantly associated with
a decreased white-blood-cell count and absolute neutrophil count
nadirs.23 The inclusion of osseous structures within the optimiza-
tion process may be a viable solution to decrease the rate, intensity
and duration of haematologic toxicity. In our patient cohort,
treatment breaks were seen in 30% of patients with a short mean
duration of 2.2 days. Those having a break of $3 days were 10%.
The RTOG 05-29 trial reported an OTT of 43 days (range 32–
59 days), similar to that of our cohort (43 days; range 38–54 days)
and shorter than that reported in the RTOG 98-11 trial (49 days;
range 4–100 days). Up to 49% of patients experienced treatment
breaks, with a higher rate than in our data set (30%), but a lower
one than that in RTOG 98-11. On the contrary, a lower median
interruption time was seen than in ours (0 vs 2.2 days as median
time) and in RTOG 98-11 (3 days). Actuarial rates of DFS, CSS and
OS were 84.5%, 85.2% and 85–2% at 2 years, respectively. More-
over, the actuarial probability of being alive at 2 years without
a colostomy was 77.9%. These results are comparable with those
reported in the RTOG 98-11 trial. Our findings can be considered
as a further proof of principle about the feasibility of IMRT in the
combination therapy of anal cancer, with similar clinical outcomes to
those of the literature, suggesting that on an average, IMRT does not
decrease tumour control, survival and sphincter preservation rate if
compared with conventional techniques. Acute skin toxicity and
compliance to treatment are improved with respect to historical data.
Treatment breaks have a lower rate and duration than the series
employing standard techniques. No dosimetric parameters were
found to be predictive for acute toxicity in our series, except a bor-
derline statistical significance for V20 to the external genitalia at uni-
variate analysis. This may reflect the intrinsic difficulty with respect to
dose constraints to the genitalia owing to the close proximity to high-
dose target volumes. In our series, external genitalia constraints could
not be met in 23/39 (59%) patients for V20, in 15/39 (38%) patients
for V30 and in 29/39 (74%) patients for V40. Thus, a specific focus
should be addressed to these structures during the planning process.
Furthermore, we employed a SIB approach as in the RTOG 0529
trial, delivering a different daily dose to selected treatment volumes
during the same treatment fraction. SIB provides dosimetric benefits
in terms of target volume dose conformity and homogeneity and
normal tissue sparing in the setting of anal cancer. This is noteworthy
as the SIB approach is able to shorten the OTT with a consequent
potential benefit on treatment outcomes In general, our finding
further supports the implementation and use of IMRTon a routine
basis for the treatment of cancer of the anal canal in combination
with concurrent CT.
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